Case Study: Pfizer’s BESPONSA® (inotuzumab ozogamicin) – drug development to U.S. FDA Approval
Brand Name: BESPONSA® Company: Pfizer Molecule: Inotuzumab ozogamicin Approved Indication: Treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia... Read More